Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

2.510 -0.040 (-1.57%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
4 Analysts Have This to Say About Fulcrum Therapeutics
Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings: 
Via Benzinga
10 Biggest Price Target Changes For Monday
RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading. 
Via Benzinga
Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Friday. 
Via Benzinga
Analyst Ratings for Fulcrum Therapeutics
Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings: 
Via Benzinga
Recap: Fulcrum Therapeutics Q1 Earnings
Fulcrum Therapeutics (NASDAQ:FULC) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump
U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling around 400 points on Friday. 
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial. 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Inflation Rate Accelerates to 8.6%
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Friday. 
Via Benzinga
Looking Into Fulcrum Therapeutics's Return On Capital Employed
Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q1 sales of $2.59 million. Earnings fell to a loss of $25.93 million, resulting in a 10.41% decrease from last quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Earnings Preview: Fulcrum Therapeutics
Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum... 
Via Benzinga
Fulcrum Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Fulcrum Therapeutics (NASDAQ:FULC) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Fulcrum Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q4 sales of $5.06 million. Earnings fell to a loss of $23.48 million, resulting in a 13.36% decrease from last... 
Via Benzinga
Fulcrum Therapeutics To Start Late-Stage Losmapimod Trial In Rare Muscle Wasting Disorder
Fulcrum Therapeutics Inc (NASDAQ: FULC) plans to initiate REACH, a Phase 3 trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), in Q2 of 2022. ... 
Via Benzinga
Fulcrum Therapeutics: Q4 Earnings Insights
Fulcrum Therapeutics (NASDAQ:FULC) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
Earnings Preview For Fulcrum Therapeutics
Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement.... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment
Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market value of their outstanding shares is at $431.7... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback